Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (November 2022)
12 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 29, 2022
Slide 1: 2022 Annual General Meeting
2022 Annual General Meeting 29 November 2022 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, affordable and highly accurate blood test for the detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. Market-ready with operational revenues expected in FY’23. C
Slide 4: ColoSTAT Highlights
ColoSTAT® Highlights Disruptive and transformative technology More affordable and easier to administer Globally addressable markets Performance better than market standard Manufacturing & Patents secured Operational revenues expected in FY’23 Platform Technology Extension Underway 4
Slide 5: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 $6,000,000 Share Price (at 7 November 2022) $1.10 $2.00 $5,000,000 Shares on Issue 217.2 M $1.50 $4,000,000 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $238.9 M $2,000,000 $0.50 $1,000,000 Cash in b
Slide 6: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$39 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million2 $12Bn
Slide 7: Poor acceptability of faecal tests is a significant limitation
Poor acceptability of faecal tests is a significant limitation to the performance of current CRC screening Patients report inconvenience of sample collection, aversion with the procedure and general fear as significant barriers to CRC screening1-3 An observational study1 in over 1,000 people in the
Slide 8: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? Unlike the FIT, ColoSTAT® is specific for colorectal cancer – not just blood in faeces. How it works ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate with existing pathology lab infrastructure. ColoSTAT® Test-Kit Algori
Slide 9: ColoSTAT Performance
ColoSTAT® Performance ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments ColoSTAT® Sensitivity Performance Comparison • Highly Accurate ColoSTAT® was shown to be 35% more accurate at detecting colorectal cancer than the 85% current market sta
Slide 10: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Reduced Government highe
Slide 11: Milestones Delivered and Future Catalysts
Milestones Delivered and Future Catalysts Completion of Core CE Mark TGA Inclusion of Clinical trial Commenced the ColoSTAT® technology (Europe) and Submission RHY into the All (Study 7) Platform prototype test- technically expanded to UK (Australia) Ordinaries Index successfully Technology kit vali
Slide 12: Glenn Gilbert CEO and Managing Director, Rhythm Biosciences
Glenn Gilbert CEO and Managing Director, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 12
Rhythm Biosciences — Shareholder Meeting (November 2022) on 6ix